Skip to NavigationSkip to content

20 year old man died after leukaemia cell was accidently mixed into CAR T therapy

Published on 02/10/18 at 10:46am
Image Credit: Jimjamjak

A 20 year old man died after a single leukaemia cell accidentally ended up in a batch of cells that were being manufactured into a CAR-T cell therapy, according to researchers at the University of Pennsylvania.

The mistake, which brought about a fatal relapse in the 20 year old man, was reported in the journal Nature Medicine.

The patient was entered into an early stage trial of CTL019, which was eventually licensed to Novartis and sold under the brand name Kymriah.  

Dr Marco Ruella who led the trial said the case was “exceptionally rare” as he noted that the findings were disclosed to the US FDA prior to the treatment’s approval.

However the authors suggested that better manufacturing technologies were needed “that can purge residual contaminating tumor cells from engineered T cells.”

Novartis also noted that they use a different manufacturing process to the one used by the University of Pennsylvania.

The Swiss multinational commented in a statement: “We are not aware of any cases of this happening in the more than 400 patients treated with CTL019/Kymriah manufactured by Novartis for clinical trials or the commercial setting.”

Louis Goss

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches